Voorspellende waarde van soluble mesothelin-related peptide, CEA, Cyfra 21-1 and CA 125 bij patiënten met pleuravocht.

Diagnostic value of soluble mesothelin-related peptide (SMRP), CEA, CA125 and CYFRA 21-1 for malignancy in pleural fluid, the mesothelin study.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON20116

Enrollment

120

Registered

2010-06-07

Start date

2010-08-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pleural effusion, tumour markers, mesothelin. pleuravocht, tumormarkers, mesotheline

Interventions

1. Thoracentesis

2. Venapuncture.

Eligibility

Inclusion criteria

Inclusion criteria: 1. Pleural fluid; 2. Age over 18 years; 3. Clinical indication for analysing pleural fluid.

Exclusion criteria

Exclusion criteria: 1. Known cause of the pleural fluid; 2. Clinical and/or radiological suspicion for pleural empyema; 3. Malignancy in the 2 years before presentation.

Design outcomes

Primary

Measure	Time frame
To test the diagnostic capacity for malignancy in pleural fluid of the tumour markers SMRP, CEA, Cyfra 21-1 and Ca 125 by patients presenting with pleural fluid without any known or suspected cause.	—

Secondary

Measure	Time frame
The prognostic capacity of the same markers in malignant pleural disease.	—

Contacts

Public ContactJ.H. Schouwink

Postbus 50.000

J.Schouwink@mst.nl+31 (0)53 4872610

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)